Docket No: AM100632D1

Patent

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of:

Thomas Argentieri

Application No.:

10/635.081

Group Art No.:

1614

Filed:

August 6, 2003

Examiner:

Phyllis G. Spivack

For:

Methods For Treating Hyperactive Gastric Motility

Confirmation No.: Customer Number: 7223 25291

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Preliminary Statements 1.

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

## CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper and the documents referred to as enclosed therein are being facsimile transmitted to the United States Patent and Trademark Office, central facsimile number 703 872 9306 on the date shown below:

October 25, 2004

Page 1 of 3 Information Disclosure Statement-Pend

Docket No: AM100632D1 Patent

2.	Identi This I a. b. c. d.	ificatio	ation Disclosure Statement is filed within three months of the filing date of the application. is filed before the mailing date of a first Office Action on the merits. is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p). is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).
3.		Cert The	ification under 37 CFR 1.97(e) and 1.704(d) undersigned attorney certifies
	a.		that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the
	b.		filing of the statement, or that no item of information contained in the Information Disclosure that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to
	c.		the filing of the statement. certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.
	⊠	A I att ap	wly Cited Information egible copy of the patents, publications or other information cited on the egible copy of the patents, publications or other information cited on the ached form PTO 1449 is enclosed, except that no copy of a pending U.S. plication is enclosed, and if this patent application was filed or entered the tional stage after June 30, 2003, no copy of a U.S. patent or U.S. patent plication publication is enclosed.
		No fo to	reviously Cited Information copy of the patents, publications or other information cited on the attached rm PTO-1449 is enclosed because it has been previously cited by or submitted the Office in a prior application which is relied upon for an earlier filing date ander 35 USC 120.  The rior application is Application Number filed on of for

Docket No: AM100632D1

Patent

		·							
a. b.	Concise Explanation Documents cited above which are not in the English Language have been explained in the specification. have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.								
Form	PTO	-1449 is enclosed in duplicate.							
$\boxtimes$	Fees	Fee for filing under 37 CFR 1.97(d) or (e) Fee: \$180.00							
Char	ge De	Payment of Fees: posit Account No. 01-1425 in the amount of \$180.00							

A duplicate of this statement is enclosed.

Instructions as to Overpayment/Underpayment: Credit any overpayment and charge any underpayment to Deposit Account No. 01-1425.

> Attorney for Applicants Reg. No. 39,224

Wyeth Patent Law Department Five Giralda Farms Madison, NJ 07940 Tel. No. 484 865 8610

								Сот	plet	e If Known			
Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT							Application Number 10/635,081						
							Filing Date			August 6, 2003			
							First Named Inventor			Argentieri			
							Group Art Unit			1614			
(use as many sheets as necessary)						ŀ	Examiner Name		Phyllis G. Spivack				
	Tof 1			Attorney Docket Number		AM	AM100632D1						
U.S. PATENT DOCUMENTS													
					L	J.S. PAT	ENT DOCUM	EN12		Pi	ages, Columns, Lines,		
<del></del> -		U.S. Patent Document			-	Name of Date	ntee or Applicant	Date of Publicati Cited Docume			Where Relevant Passages or Relevant		
Examiner Initials*	Cite No.	Number		Kind Code	1	of Cited	Document	MIM-DD-YYY		· •	Figures Appear		
rumana.	NO.	(If known) (If Known)			1			07-22-2003	3				
	1. 6,596,759 B2 Abe et al.			107-22-2000									
					FO	REIGN F	ATENT DOC	UMENTS					
	Cite No.	Foreign Patent Document				Name of Par		entee or	Date of Publication of Cited Document MM-DD-YYYY		Pages, Columns, Unes, Where Relevant Passages or Relevant	7	
Examiner !nitials*		Office	ļ <sup>-</sup>	Number		Kind Code (tr Known)	Applicant of Cited document		MINE-CO-TTTT		Figures Appear	┤┯┰	
						<del>                                     </del>							
	2.		L							CLIMENTS			
			OTHER	PRIOF	AR	T NOI	N PATENT LI	ERATUR		nieta), title of the		T _	
<del></del>	Cite	OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS  OTHER PRIOR ART — NON PATENT LITERS), title of the article (when appropriate), title of the include name of the author (in CAPITAL LETTERS), title of the appropriate), title of the include name of the author (in CAPITAL LETTERS), title of the appropriate), title of the include name of the author (in CAPITAL LETTERS), title of the appropriate), title of the										T	
Examiner Initials*	No.		Include name of the author (in CAPITAL LETTERS), title of the arctics (what approximation of the author (in CAPITAL LETTERS), title of the arctic (what approximation of the arc										
<u> </u>	3.	SCHRODER, Rikke et al., Neuropharmacology, 40, 888-898 (2001)											
	4.	SIMS, Stephen et al., J. Physiol., 367, 503-529 (1985)											

<del></del>		Date	
Examiner	•	Considered	
Signature			the Mark in conformance and not considered. Include copy of this form with n

\*EXAMINER: Initial II reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to eppticant.